Kaname Yamamoto

523 total citations
22 papers, 411 citations indexed

About

Kaname Yamamoto is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kaname Yamamoto has authored 22 papers receiving a total of 411 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kaname Yamamoto's work include Colorectal Cancer Treatments and Studies (5 papers), Glycosylation and Glycoproteins Research (4 papers) and Bone health and treatments (4 papers). Kaname Yamamoto is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Glycosylation and Glycoproteins Research (4 papers) and Bone health and treatments (4 papers). Kaname Yamamoto collaborates with scholars based in Japan, United States and Italy. Kaname Yamamoto's co-authors include Masamichi Sugimoto, Toshiki Iwai, Keigo Yorozu, Mitsue Kurasawa, Daiko Wakita, Mieko Yanagisawa, Koh Furugaki, Masakazu Nagashima, Suguru Harada and Nobuyuki Ishikura and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Kaname Yamamoto

22 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaname Yamamoto Japan 11 236 157 124 82 38 22 411
Carolien Boeckx Belgium 12 225 1.0× 155 1.0× 109 0.9× 38 0.5× 23 0.6× 15 374
Lele Miao China 10 240 1.0× 97 0.6× 41 0.3× 107 1.3× 46 1.2× 20 408
H. Kasparu Austria 10 227 1.0× 167 1.1× 79 0.6× 75 0.9× 63 1.7× 28 513
J. Rothenstein Canada 13 297 1.3× 116 0.7× 305 2.5× 35 0.4× 14 0.4× 25 530
Stanislav Lechpammer United States 10 96 0.4× 136 0.9× 126 1.0× 39 0.5× 101 2.7× 29 439
Pernelle Lavaud France 12 377 1.6× 94 0.6× 290 2.3× 78 1.0× 70 1.8× 71 551
Melinda Laine Hsu United States 11 214 0.9× 160 1.0× 119 1.0× 111 1.4× 31 0.8× 28 422
Natalie Compton United Kingdom 9 255 1.1× 126 0.8× 164 1.3× 16 0.2× 22 0.6× 14 421
Si‐Lin Koo Singapore 11 299 1.3× 130 0.8× 165 1.3× 147 1.8× 18 0.5× 28 535
Betül T. Yesilyurt Belgium 8 194 0.8× 184 1.2× 89 0.7× 57 0.7× 17 0.4× 9 452

Countries citing papers authored by Kaname Yamamoto

Since Specialization
Citations

This map shows the geographic impact of Kaname Yamamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaname Yamamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaname Yamamoto more than expected).

Fields of papers citing papers by Kaname Yamamoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaname Yamamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaname Yamamoto. The network helps show where Kaname Yamamoto may publish in the future.

Co-authorship network of co-authors of Kaname Yamamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Kaname Yamamoto. A scholar is included among the top collaborators of Kaname Yamamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaname Yamamoto. Kaname Yamamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wakita, Daiko, Toshiki Iwai, Suguru Harada, et al.. (2019). Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. Anticancer Research. 39(4). 1749–1760. 35 indexed citations
2.
Sugimoto, Masamichi, Daiko Wakita, Makoto Monnai, et al.. (2019). Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model. Clinical & Experimental Metastasis. 37(1). 199–207. 25 indexed citations
3.
4.
Yamamoto, Kaname, et al.. (2017). MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells. Scientific Reports. 7(1). 16763–16763. 10 indexed citations
5.
Ishikura, Nobuyuki, Mieko Yanagisawa, Toshiki Iwai, et al.. (2017). Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non–small Cell Lung Cancer Xenograft Models. Anticancer Research. 37(2). 623–630. 6 indexed citations
6.
Gerdol, Marco, Yuki Fujii, Imtiaj Hasan, et al.. (2017). The purplish bifurcate mussel Mytilisepta virgata gene expression atlas reveals a remarkable tissue functional specialization. BMC Genomics. 18(1). 590–590. 32 indexed citations
7.
Yanagisawa, Mieko, Keigo Yorozu, Mitsue Kurasawa, et al.. (2017). Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. International Journal of Oncology. 51(2). 425–434. 64 indexed citations
8.
9.
Furugaki, Koh, Toshiki Iwai, Keigo Yorozu, et al.. (2015). Impact of bevacizumab in combination with erlotinib on EGFR‐mutated non–small cell lung cancer xenograft models with T790M mutation or MET amplification. International Journal of Cancer. 138(4). 1024–1032. 31 indexed citations
10.
Harada, Suguru, Mieko Yanagisawa, Keigo Yorozu, et al.. (2015). Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Molecular and Clinical Oncology. 3(5). 987–994. 6 indexed citations
11.
Harada, Suguru, Mieko Yanagisawa, Toshiki Iwai, et al.. (2013). Antitumor activities of bevacizumab for KRAS, BRAF, and PIK3CA mutated human colorectal cancer xenograft models.. Journal of Clinical Oncology. 31(4_suppl). 362–362. 2 indexed citations
12.
Fuse, Akira, Tetsu Okumura, Reo Fukuda, et al.. (2013). New Information Technology Tools for a Medical Command System for Mass Decontamination. Prehospital and Disaster Medicine. 28(3). 298–300. 7 indexed citations
13.
Yanagisawa, Mieko, et al.. (2011). Abstract 4256: Antitumor activity of capecitabine in combination with bevacizumab and cyclophosphamide in triple-negative breast cancer xenograft model. Cancer Research. 71(8_Supplement). 4256–4256. 1 indexed citations
14.
Fujimoto-Ouchi, Kaori, Fumiko Sekiguchi, Kaname Yamamoto, et al.. (2009). Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy. Cancer Chemotherapy and Pharmacology. 66(2). 269–276. 18 indexed citations
15.
Yamamoto, Kaname & Kiyohide Fushimi. (2009). Travel of patients to distant hospitals for elective surgery in Japan: A cross-sectional analysis of a nationally representative sample. Surgery Today. 39(9). 758–763. 8 indexed citations
16.
17.
18.
19.
Yamamoto, Kaname, et al.. (1994). Comparative study of human-PTH(1-84) and human-PTH(1-34) in the chick hypercalcemia bioassay. Journal of Bone and Mineral Metabolism. 12(S1). S135–S137. 3 indexed citations
20.
Taki, T., Kaname Yamamoto, Kazuo Ishii, et al.. (1990). Accumulation of gangliosides with N-acetylneuraminosyl(alpha 2-6)lactosamine structure in primary human hepatoma.. PubMed. 50(4). 1284–90. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carolien Boeckx Breakdown of academic impact, for papers by Lele Miao Breakdown of academic impact, for papers by H. Kasparu Breakdown of academic impact, for papers by J. Rothenstein Breakdown of academic impact, for papers by Stanislav Lechpammer Breakdown of academic impact, for papers by Pernelle Lavaud Breakdown of academic impact, for papers by Melinda Laine Hsu Breakdown of academic impact, for papers by Natalie Compton Breakdown of academic impact, for papers by Si‐Lin Koo Breakdown of academic impact, for papers by Betül T. Yesilyurt
Rankless by CCL
2026